Anebulo Pharmaceuticals, Inc.

NasdaqCM ANEB

Anebulo Pharmaceuticals, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2024

Anebulo Pharmaceuticals, Inc. Total Non-Current Liabilities is NA for the quarter ending September 30, 2024. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NasdaqCM: ANEB

Anebulo Pharmaceuticals, Inc.

CEO	Mr. Richard Anthony Cunningham
IPO Date	May 7, 2021
Location	United States
Headquarters	1415 Ranch Road 620 South
Employees	2
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Key trends

Past 5 years